-
公开(公告)号:US20100305126A1
公开(公告)日:2010-12-02
申请号:US12788008
申请日:2010-05-26
申请人: Richard F. Clark , Randy L. Bell , Nwe Y. Ba-maung , Scott A. Erickson , Steve D. Fidanze , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang , Jieyi Wang
发明人: Richard F. Clark , Randy L. Bell , Nwe Y. Ba-maung , Scott A. Erickson , Steve D. Fidanze , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang , Jieyi Wang
IPC分类号: A61K31/5377 , C07D403/14 , C07D413/14 , A61K31/506 , A61P35/00
CPC分类号: C07D471/04 , C07D487/04 , C07D513/04
摘要: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R.
摘要翻译: 本发明涉及式(I)化合物或其药学上可接受的盐或溶剂化物,其中在说明书中定义了G1,R2,R3,R4,R5,n,p,q,Ar1和Ar2。 本发明还涉及制备所述化合物的方法,以及包含所述化合物的组合物,其可用于抑制诸如IGF-1R的激酶。
-
公开(公告)号:US07491718B2
公开(公告)日:2009-02-17
申请号:US10681784
申请日:2003-10-08
申请人: Kenneth M. Comess , Scott A. Erickson , Jack Henkin , Douglas M. Kalvin , Megumi Kawai , Ki H. Kim , Nwe Y. BaMaung , Chang Hoon Park , George S. Sheppard , Anil Vasudevan , Jieyi Wang , David M. Barnes , Steve D. Fidanze , Lawrence Kolaczkowski , Robert A. Mantei , David C. Park , William J. Sanders , Jason S. Tedrow , Gary T. Wang
发明人: Kenneth M. Comess , Scott A. Erickson , Jack Henkin , Douglas M. Kalvin , Megumi Kawai , Ki H. Kim , Nwe Y. BaMaung , Chang Hoon Park , George S. Sheppard , Anil Vasudevan , Jieyi Wang , David M. Barnes , Steve D. Fidanze , Lawrence Kolaczkowski , Robert A. Mantei , David C. Park , William J. Sanders , Jason S. Tedrow , Gary T. Wang
IPC分类号: A61K31/435 , A61K31/535 , A61K31/4965 , A61K31/415 , A61K31/40 , A61K31/425 , C07D265/30 , C07D241/04 , C07D279/12 , C07D277/02 , C07D263/02 , C07C255/03 , A61K31/42
CPC分类号: C07D213/70 , C07D231/18
摘要: Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
摘要翻译: 描述了具有甲硫氨酸氨基肽酶-2抑制剂(MetAP2)的化合物。 还描述了包含该化合物的药物组合物,使用该化合物的治疗方法,抑制血管生成的方法和治疗癌症的方法。
-
23.Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition 有权
标题翻译: 咪唑并吡啶作为多靶向激酶抑制的新型支架公开(公告)号:US09051315B2
公开(公告)日:2015-06-09
申请号:US12906681
申请日:2010-10-18
申请人: Nwe Y. Ba-maung , Richard F. Clark , Scott A. Erickson , Steve D. Fidanze , Megumi Kawai , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang
发明人: Nwe Y. Ba-maung , Richard F. Clark , Scott A. Erickson , Steve D. Fidanze , Megumi Kawai , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang
IPC分类号: A61K31/55 , A61K31/535 , A61K31/497 , C07D223/14 , C07D413/04 , C07D239/02 , C07D471/04
CPC分类号: C07D471/04
摘要: Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.
摘要翻译: 公开了抑制蛋白激酶的化合物,含有化合物的组合物和使用该化合物治疗疾病的方法。
-
公开(公告)号:US08536180B2
公开(公告)日:2013-09-17
申请号:US12787915
申请日:2010-05-26
申请人: Richard F. Clark , Nwe Y. Ba-maung , Scott A. Erickson , Steve D. Fidanze , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang , Jieyi Wang , Randy L. Bell
发明人: Richard F. Clark , Nwe Y. Ba-maung , Scott A. Erickson , Steve D. Fidanze , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang , Jieyi Wang , Randy L. Bell
IPC分类号: A61K31/497 , A61K31/535 , A61K31/505 , C07D413/14 , C07D403/14
CPC分类号: C07D471/04 , C07D403/14 , C07D487/04 , C07D513/04
摘要: Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R2, R3, n, p, Ar1, and Ar2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.
摘要翻译: 本文描述了式(I)化合物或其药学上可接受的盐或溶剂合物,其中在说明书中定义了G1,L1,R2,R3,n,p,Ar1和Ar2。 还公开了制备所述化合物的方法,以及包含所述化合物的组合物,其可用于抑制激酶如IGF-1R。
-
公开(公告)号:US08486933B2
公开(公告)日:2013-07-16
申请号:US12787735
申请日:2010-05-26
申请人: Gary T. Wang , Robert A. Mantei , Scott A. Erickson , Steve D. Fidanze , George S. Sheppard , Jieyi Wang , Randy L. Bell
发明人: Gary T. Wang , Robert A. Mantei , Scott A. Erickson , Steve D. Fidanze , George S. Sheppard , Jieyi Wang , Randy L. Bell
IPC分类号: A61K31/541 , A61K31/496 , A61K31/506 , A61K31/5377 , C07D403/14 , C07D413/14 , C07D417/14
CPC分类号: C07D403/12 , C07D401/14 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
摘要: Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L1, R1, R2, R3, R4, R5, and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.
摘要翻译: 本文描述了式(I)的化合物或其药学上可接受的盐或溶剂合物,其中在说明书中定义了L1,R1,R2,R3,R4,R5和m。 还公开了制备所述化合物的方法和含有所述化合物的组合物,其可用于抑制激酶例如IGF-1R。
-
公开(公告)号:US08354422B2
公开(公告)日:2013-01-15
申请号:US12788008
申请日:2010-05-26
申请人: Richard F. Clark , Randy L. Bell , Nwe Y. Ba-maung , Scott A. Erickson , Steve D. Fidanze , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang , Jieyi Wang
发明人: Richard F. Clark , Randy L. Bell , Nwe Y. Ba-maung , Scott A. Erickson , Steve D. Fidanze , Robert A. Mantei , George S. Sheppard , Bryan K. Sorensen , Gary T. Wang , Jieyi Wang
IPC分类号: C07D403/14 , C07D413/14 , A61K31/5377 , A61K31/506
CPC分类号: C07D471/04 , C07D487/04 , C07D513/04
摘要: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R.
摘要翻译: 本发明涉及式(I)化合物或其药学上可接受的盐或溶剂化物,其中在说明书中定义了G1,R2,R3,R4,R5,n,p,q,Ar1和Ar2。 本发明还涉及制备所述化合物的方法,以及包含所述化合物的组合物,其可用于抑制诸如IGF-1R的激酶。
-
公开(公告)号:US06887863B2
公开(公告)日:2005-05-03
申请号:US10782502
申请日:2004-02-19
申请人: Richard A. Craig , Megumi Kawai , Linda M. Lynch , Jyoti R. Patel , George S. Sheppard , Jieyi Wang , Fan Yang , Nwe Ba-Maung , Xenia Beebe Searle
发明人: Richard A. Craig , Megumi Kawai , Linda M. Lynch , Jyoti R. Patel , George S. Sheppard , Jieyi Wang , Fan Yang , Nwe Ba-Maung , Xenia Beebe Searle
IPC分类号: C07C243/34 , C07C243/38 , C07C251/86 , C07C255/44 , C07C255/57 , C07C259/06 , C07C281/02 , C07C323/48 , C07C323/60 , C07C323/63 , C07D207/40 , C07D207/416 , C07D207/50 , C07D209/14 , C07D211/98 , C07D213/42 , C07D213/77 , C07D213/81 , C07D213/86 , C07D213/87 , C07D215/42 , C07D231/38 , C07D237/20 , C07D239/28 , C07D239/42 , C07D241/44 , C07D261/18 , C07D277/54 , C07D277/56 , C07D277/82 , C07D295/15 , C07D295/32 , C07D307/68 , C07D307/84 , C07D317/68 , C07D333/38 , C07D333/68 , C07D333/72 , A61K31/33 , A61K31/16 , A61K31/20
CPC分类号: C07D207/416 , C07B2200/07 , C07C243/34 , C07C243/38 , C07C251/86 , C07C255/44 , C07C255/57 , C07C259/06 , C07C281/02 , C07C323/48 , C07C323/60 , C07C323/63 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07D207/50 , C07D209/14 , C07D211/98 , C07D213/42 , C07D213/77 , C07D213/81 , C07D213/86 , C07D213/87 , C07D215/42 , C07D231/38 , C07D237/20 , C07D239/28 , C07D239/42 , C07D241/44 , C07D261/18 , C07D277/54 , C07D277/56 , C07D277/82 , C07D295/15 , C07D295/32 , C07D307/68 , C07D307/84 , C07D317/68 , C07D333/38 , C07D333/68 , C07D333/72
摘要: Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
摘要翻译: 具有下式的化合物是甲硫氨酸氨基肽酶2(MetAP2)抑制剂,可用于抑制血管发生。 还公开了抑制哺乳动物血管生成的MetAP2抑制组合物和方法。
-
28.Substituted &bgr;-amino acid inhibitors of methionine aminopeptidase-2 失效
标题翻译: 甲硫氨酸氨基肽酶-2的取代β-氨基酸抑制剂公开(公告)号:US06242494B1
公开(公告)日:2001-06-05
申请号:US09303807
申请日:1999-04-30
申请人: Richard A. Craig , Jack Henkin , Megumi Kawai , Linda M. Lynch , Jyoti Patel , George S. Sheppard , Jieyi Wang
发明人: Richard A. Craig , Jack Henkin , Megumi Kawai , Linda M. Lynch , Jyoti Patel , George S. Sheppard , Jieyi Wang
IPC分类号: A61K31165
CPC分类号: C07D207/27 , C07C235/16 , C07C237/12 , C07C237/14 , C07C311/18 , C07C311/19 , C07C323/58 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2603/74 , C07D209/14 , C07D209/48 , C07D211/58 , C07D211/62 , C07D211/70 , C07D213/40 , C07D213/74 , C07D213/75 , C07D217/06 , C07D231/12 , C07D231/40 , C07D233/56 , C07D233/76 , C07D233/95 , C07D235/14 , C07D241/08 , C07D249/08 , C07D277/46 , C07D277/56 , C07D295/185 , C07D307/14 , C07D317/58 , C07D317/66 , C07D333/20 , C07D333/38
摘要: A class of substituted b-amino acids are potent inhibitor of methionine aminopeptidase type 2 (MetAP2) and are thus useful in inhibiting angiogenesis and disease conditions which depend upon angiogenesis for their development such as diabetic retinopathy, tumor growth, and conditions of inflammation. Pharmaceutical compounds containing the compounds and methods of inhibiting methionine aminopeptidase-2, and angiogenesis are also disclosed.
摘要翻译: 一类取代的β-氨基酸是甲硫氨酸氨基肽酶2(MetAP2)的有效抑制剂,因此可用于抑制血管生成和疾病状况,这些疾病依赖于其发展的血管生成,例如糖尿病性视网膜病变,肿瘤生长和炎症状况。 还公开了含有化合物的药物化合物和抑制甲硫氨酸氨基肽酶-2的方法和血管发生。
-
-
-
-
-
-
-